Therefore, PLA2G7 has been extensively studied in many inflammatory diseases, and the PLA2G7 inhibitors darapladib or rilapladib have already been tested in Phase II and Phase III clinical trials for treatment of Alzheimer's disease,14 diabetic retinopathy,16 and atherosclerosis.13, 15. This evidence concerns the gene PLA2G7 and diabetic retinopathy.